ArticleJournal of experimental & clinical cancer research : CR2021

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.

Emilia Alors-Perez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.